A novel cytotoxic agent for human carcinoid tumors
D A Litvak1, H T Papaconstantinou, T C Ko
1Department of Surgery, University of Texas Medical Branch, Galveston 77555-0542, USA.
Surgery
|December 17, 1998
Summary
A novel polyamine analog, BE-4-4-4-4, shows greater effectiveness than DFMO in reducing carcinoid tumor cell growth and increasing cell death. This agent holds promise as an adjuvant therapy for advanced carcinoid tumors.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Advanced carcinoid tumors require novel adjuvant therapies due to disappointing conventional treatment outcomes.
- Alpha-difluoromethylornithine (DFMO) inhibits polyamine biosynthesis and slows tumor growth but is cytostatic.
- Synthetic polyamine analogs, like BE-4-4-4-4, exhibit cytotoxicity against various human tumors.
Purpose of the Study:
- To evaluate the antiproliferative and cytotoxic efficacy of BE-4-4-4-4 compared to DFMO in human carcinoid (BON) cells in vitro.
Main Methods:
- BON cells were exposed to DFMO (5 mmol/L), varying concentrations of BE-4-4-4-4 (0.5–10 µmol/L), or a vehicle control.
- Ornithine decarboxylase activity was measured by 14CO2 production.
- Intracellular polyamine levels, cell number, and viability were assessed using chromatography, Coulter counter, and trypan blue exclusion, respectively.
Main Results:
- BE-4-4-4-4 effectively inhibited ornithine decarboxylase activity and depleted intracellular polyamines.
- BE-4-4-4-4 reduced BON cell numbers by 81% compared to control and 27% compared to DFMO.
- BE-4-4-4-4 induced a twofold increase in cell death compared to both control and DFMO treatments.
Conclusions:
- BE-4-4-4-4 demonstrates significant cytotoxicity and superior efficacy over DFMO in inhibiting human carcinoid BON cell growth.
- Polyamine analogs, exemplified by BE-4-4-4-4, represent a potential therapeutic strategy for advanced carcinoid tumors.
